Clinical trials for adolescent obesity

JAMA Pediatrics

Volumn 167, Issue 4, 2013, Pages 391-393

  Schwimmer, Jeffrey B ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; PLACEBO;

ADOLESCENT; BODY FAT; BODY MASS; BODY WEIGHT; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG EFFECT; EDITORIAL; FOOD INTAKE; HUMAN; INSULIN RELEASE; LIFESTYLE MODIFICATION; OBESITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; WEIGHT REDUCTION;

BODY MASS INDEX; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PEPTIDES; RECEPTORS, GLUCAGON; SATIETY RESPONSE; VENOMS;

EID: 84876059664     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2013.1661     Document Type: Editorial

References (23)

1. Brubaker PL. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci. 2006;1070:10-26. (Pubitemid 44126623)
2. Hayes MR. Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. Physiol Behav. 2012;106(3):413-416.
3. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagonlike peptide-1 receptor agonists on weight loss: systematic review and metaanalyses of randomised controlled trials. BMJ. 2012;344:d7771.
4. Kelly AS, Rudser KD, Nathan BM, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial [published online February 4, 2013]. JAMA Pediatr. 2013;167(4):355-360.
5. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA. 2012;307(5):483-490.
6. Robbins JM, Mallya G, Polansky M, Schwarz DF. Prevalence, disparities, and trends in obesity and severe obesity among students in the Philadelphia, Pennsylvania, school district, 2006-2010. Prev Chronic Dis. 2012;9:E145.
7. Skelton JA, Cook SR, Auinger P, Klein JD, Barlow SE. Prevalence and trends of severe obesity among US children and adolescents. Acad Pediatr. 2009;9(5):322-329.
8. Liese AD, D'Agostino RB Jr, Hamman RF, et al; SEARCH for Diabetes in Youth Study Group. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006;118(4):1510-1518. (Pubitemid 46393797)
9. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118(4):1388-1393. (Pubitemid 46393782)
10. Marcus CL, Brooks LJ, Draper KA, et al; American Academy of Pediatrics. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012;130(3):576-584.
11. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med. 2012;367(17):1577-1579.
12. Center for Drug Evaluation and Research. Guidance for Industry: Developing Products for Weight Management. Rockville, MD: Center for Drug Evaluation & Research; 2007.
13. Berkowitz RI, Fujioka K, Daniels SR, et al; Sibutramine Adolescent Study Group. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med. 2006;145(2):81-90. (Pubitemid 46780581)
14. Kirk S, Brehm B, Saelens BE, et al. Role of carbohydrate modification in weight management among obese children: a randomized clinical trial. J Pediatr. 2012;161(2):320-327, e1.
15. Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA Trial [published online November 21, 2012]. J Clin Endocrinol Metab. doi:10.1210/jc.2012-2710.
16. Savoye M, Shaw M, Dziura J, et al. Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA. 2007;297(24):2697-2704. (Pubitemid 47001095)
17. Ford AL, Hunt LP, Cooper A, Shield JP. What reduction in BMI SDS is required in obese adolescents to improve body composition and cardiometabolic health? Arch Dis Child. 2010;95(4):256-261.
18. Cole TJ, Faith MS, Pietrobelli A, Heo M. What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z-score or BMI centile? Eur J Clin Nutr. 2005;59(3):419-425. (Pubitemid 40403297)
19. Woo JG. Using body mass index Z-score among severely obese adolescents: a cautionary note. Int J Pediatr Obes. 2009;4(4):405-410.
20. Ho M, Garnett SP, Baur L, et al. Effectiveness of lifestyle interventions in child obesity: systematic review with meta-analysis. Pediatrics. 2012;130(6):e1647-e1671.
21. NBC. The Biggest Loser. http://www.nbc.com/the-biggest-loser/. Accessed November 30, 2012.
22. US Food and Drug Administration. FDA approves Belviq to treat some overweight or obese adults. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm309993.htm. Accessed December 5, 2012.
23. US Food and Drug Administration. FDA approves weight-management drug Qsymia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm. Accessed December 5, 2012.